Department of Medicine, Division of Biostatistics and Epidemiology, Medical University of South Carolina, Charleston, USA.
Ann Epidemiol. 2012 Jan;22(1):1-8. doi: 10.1016/j.annepidem.2011.10.007.
We assessed medication use and associated costs among 8- and 15-year-old children with autism spectrum disorders (ASD) identified by the South Carolina Autism and Developmental Disabilities Monitoring (SCADDM) Network.
All Medicaid-eligible SCADDM-identified children with ASD from surveillance years 2006 and 2007 were included (n = 263). Children were classified as ASD cases when documented behaviors consistent with the DSM-IV-TR criteria for autistic disorder, Asperger disorder, or pervasive developmental disorder-not otherwise specified were present in health and education evaluation records. Medication and cost data were obtained by linking population-based and Medicaid data.
All 263 SCADDM-identified children had Medicaid data available; 56% (n = 147) had a prescription of any type, 40% (n = 105) used psychotropic medication, and 20% (n = 52) used multiple psychotropic classes during the study period. Common combinations were (1) attention deficit hyperactivity disorder medications and an antihypertensive, antidepressant or antipsychotic; and (2) antidepressants and an antipsychotic. Multiple psychotropic classes were more common among older children. Both the overall distribution of the number of prescription claims and medication costs varied significantly by age.
Results confirm that medication use in ASD, alone or in combination, is common, costly, and may increase with age.
我们评估了通过南卡罗来纳州自闭症和发育障碍监测网络(SCADDM)确定的患有自闭症谱系障碍(ASD)的 8 岁和 15 岁儿童的用药情况和相关费用。
包括符合 DSM-IV-TR 自闭症障碍、阿斯伯格障碍或未特定的广泛性发育障碍标准的行为在健康和教育评估记录中出现的所有 2006 年和 2007 年 SCADDM 监测年中符合医疗补助资格的 ASD 儿童(n = 263)。药物和费用数据通过将基于人群和医疗补助的数据进行关联获得。
所有 263 名 SCADDM 确定的儿童都有医疗补助数据可用;56%(n = 147)有任何类型的处方,40%(n = 105)使用精神药物,20%(n = 52)在研究期间使用多种精神药物类别。常见的组合是(1)注意力缺陷多动障碍药物和降压药、抗抑郁药或抗精神病药;和(2)抗抑郁药和抗精神病药。年龄较大的儿童更常使用多种精神药物类别。处方数量和药物费用的总体分布都随年龄显著变化。
结果证实,ASD 单独或联合用药很常见,费用高昂,并且可能随着年龄的增长而增加。